Clinical trials
Phase 3 Hyperlipoproteinemia Type II trials in Norway
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
10 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| Amgen | 1 |
| LIB Therapeutics LLC | 1 |
| Merck Sharp & Dohme LLC | 1 |
| NewAmsterdam Pharma | 1 |
| Nordlandssykehuset HF | 1 |
| Novartis Pharmaceuticals | 1 |
| Pfizer | 1 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperlipoproteinemia Type II | 10 |
| Hypercholesterolemia | 4 |
| Homozygous Familial Hypercholesterolemia | 2 |
| Dyslipidemias | 1 |
| Genetic Diseases, Inborn | 1 |
| Hyperlipidemias | 1 |
| Hyperlipoproteinemias | 1 |
| Lipid Metabolism Disorders | 1 |
| Lipid Metabolism, Inborn Errors | 1 |
| Metabolic Diseases | 1 |
Trials
Showing 1 to 10 of 10. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.